The Journal of Steroid Biochemistry and Molecular Biology 2014-07-01

Use of SERMs for treatment in postmenopausal women

JoAnn V. Pinkerton, Semara Thomas

Index: J. Steroid Biochem. Mol. Biol. 142 , 142-54, (2014)

Full Text: HTML

Abstract

• FDA approved selective estrogen receptor modulators (SERMs) prevent and treat breast cancer, osteoporosis and dyspareunia. • SERMs have varying agonist and antagonist activities at the level of the estrogen receptor (ER) in target tissues. • Targeted agonist effects of SERMs are hot flashes, lipids, bone, vagina, and brain. • Antagonist SERM effects are desired in breast and endometrium. • The first tissue selective estrogen complex (TSEC) pairs the SERM bazedoxifene with conjugated equine estrogens.